Evolus (EOLS) Set to Announce Earnings on Tuesday

Evolus (NASDAQ:EOLS) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Evolus to post earnings of ($0.07) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The company had revenue of $61.00 million during the quarter, compared to the consensus estimate of $61.14 million. On average, analysts expect Evolus to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolus Trading Up 0.6 %

Shares of Evolus stock opened at $13.30 on Monday. Evolus has a fifty-two week low of $7.07 and a fifty-two week high of $15.43. The stock has a 50 day moving average of $13.31 and a 200 day moving average of $11.44.

Insider Transactions at Evolus

In related news, insider David Moatazedi sold 6,236 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $13.86, for a total transaction of $86,430.96. Following the transaction, the insider now owns 689,614 shares of the company’s stock, valued at $9,558,050.04. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CFO Sandra Beaver sold 5,672 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total transaction of $78,954.24. Following the transaction, the chief financial officer now owns 154,201 shares of the company’s stock, valued at $2,146,477.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David Moatazedi sold 6,236 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $13.86, for a total value of $86,430.96. Following the transaction, the insider now directly owns 689,614 shares in the company, valued at approximately $9,558,050.04. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 49,038 shares of company stock worth $674,232. Corporate insiders own 5.40% of the company’s stock.

Wall Street Analyst Weigh In

EOLS has been the topic of several analyst reports. Barclays upgraded Evolus from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $10.00 to $16.00 in a research note on Monday, January 29th. HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research note on Friday, March 1st. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research note on Wednesday, April 10th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.